Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Use Of Highly Selective NSAID Comparator In Arcoxia Trials Remains Controversial

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck’s Arcoxia should not be approved based on a comparison to diclofenac in the MEDAL studies, Cleveland Clinic’s Nissen says.

You may also be interested in...



Pfizer Will Highlight Celebrex Safety In ’07

Firm to address cardiovascular safety for the COX-2 inhibitor in a new DTC advertising campaign.

Pfizer Will Highlight Celebrex Safety In ’07

Firm to address cardiovascular safety for the COX-2 inhibitor in a new DTC advertising campaign.

Celebrex JRA Indication To Be Evaluated By FDA Advisory Committee

Lack of long-term safety data “poses a special challenge” in weighing risks and benefits, FDA says in briefing documents.

Related Content

Topics

UsernamePublicRestriction

Register

OM006665

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel